| Primary |
| Metastatic Renal Cell Carcinoma |
20.9% |
| Hepatitis C |
19.1% |
| Chronic Hepatitis C |
12.9% |
| Malignant Melanoma |
9.4% |
| Product Used For Unknown Indication |
7.3% |
| Renal Cell Carcinoma |
5.4% |
| Drug Use For Unknown Indication |
4.1% |
| Metastatic Malignant Melanoma |
3.3% |
| Prophylaxis |
3.2% |
| Multiple Myeloma |
3.0% |
| Hypertension |
2.5% |
| Gout |
1.9% |
| Hypertonia |
1.4% |
| Multiple Sclerosis |
1.0% |
| Bone Pain |
0.8% |
| Diabetes Mellitus |
0.8% |
| Renal Cancer Metastatic |
0.8% |
| Teratoma |
0.8% |
| Non-hodgkin's Lymphoma |
0.6% |
| Pain |
0.6% |
|
| Hepatitis C |
16.9% |
| Disease Progression |
10.1% |
| Hepatic Neoplasm Malignant |
8.4% |
| Weight Decreased |
7.3% |
| Pulmonary Embolism |
6.7% |
| Viral Load Increased |
5.1% |
| Vomiting |
5.1% |
| Depression |
4.5% |
| Nausea |
3.9% |
| Pyrexia |
3.9% |
| Malignant Melanoma |
3.4% |
| Malignant Neoplasm Progression |
3.4% |
| Death |
2.8% |
| Portal Vein Thrombosis |
2.8% |
| Renal Failure Acute |
2.8% |
| Thrombocytopenia |
2.8% |
| Upper Gastrointestinal Haemorrhage |
2.8% |
| White Blood Cell Count Decreased |
2.8% |
| Gliosis |
2.2% |
| Hyponatraemia |
2.2% |
|
| Secondary |
| Metastatic Renal Cell Carcinoma |
22.3% |
| Hepatitis C |
20.0% |
| B-cell Lymphoma |
16.2% |
| Drug Use For Unknown Indication |
9.5% |
| Renal Cell Carcinoma |
7.4% |
| Chronic Hepatitis C |
4.6% |
| Product Used For Unknown Indication |
3.5% |
| Renal Cancer |
2.5% |
| Hypertension |
1.9% |
| Malignant Melanoma |
1.6% |
| Chronic Myeloid Leukaemia |
1.5% |
| Hiv Infection |
1.5% |
| Prophylaxis |
1.2% |
| Gout |
1.1% |
| Multiple Myeloma |
1.1% |
| Hepatitis |
0.9% |
| Metastases To Central Nervous System |
0.9% |
| Non-hodgkin's Lymphoma Stage Iii |
0.9% |
| Renal Cancer Metastatic |
0.9% |
| Cardiac Failure |
0.7% |
|
| Hepatic Neoplasm Malignant |
10.9% |
| Vomiting |
8.8% |
| Thrombocytopenia |
8.2% |
| Rash |
6.1% |
| Anaemia |
5.4% |
| Hip Fracture |
5.4% |
| Inappropriate Antidiuretic Hormone Secretion |
5.4% |
| Pyrexia |
5.4% |
| Upper Gastrointestinal Haemorrhage |
5.4% |
| Disease Progression |
4.8% |
| Nausea |
4.8% |
| Pulmonary Embolism |
4.1% |
| Prostate Cancer |
3.4% |
| Pruritus |
3.4% |
| Retinopathy |
3.4% |
| Weight Decreased |
3.4% |
| White Blood Cell Count Decreased |
3.4% |
| Acute Myeloid Leukaemia |
2.7% |
| Epilepsy |
2.7% |
| Stomatitis |
2.7% |
|
| Concomitant |
| Hepatitis C |
22.3% |
| Drug Use For Unknown Indication |
18.5% |
| Lung Neoplasm Malignant |
7.6% |
| Chronic Hepatitis C |
7.0% |
| Eczema |
5.7% |
| Hepatic Cirrhosis |
5.1% |
| Hiv Infection |
5.1% |
| Pain |
4.5% |
| Product Used For Unknown Indication |
3.2% |
| Schizophrenia |
3.2% |
| Colitis |
2.5% |
| Immunosuppression |
2.5% |
| Metastases To Lung |
2.5% |
| Behcet's Syndrome |
1.9% |
| Liver Disorder |
1.9% |
| Epididymitis |
1.3% |
| Hypertension |
1.3% |
| Insomnia |
1.3% |
| Liver Transplant |
1.3% |
| Renal Cancer Metastatic |
1.3% |
|
| Weight Increased |
28.6% |
| White Blood Cell Count Decreased |
16.7% |
| Blindness |
7.1% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
4.8% |
| Keratitis Bacterial |
4.8% |
| Weight Decreased |
4.8% |
| Adverse Event |
2.4% |
| Anaemia |
2.4% |
| Arthritis |
2.4% |
| Death |
2.4% |
| Disease Progression |
2.4% |
| Dyspnoea |
2.4% |
| Erythema |
2.4% |
| Fatigue |
2.4% |
| Headache |
2.4% |
| Hepatic Cirrhosis |
2.4% |
| Metastases To Central Nervous System |
2.4% |
| Oedema Peripheral |
2.4% |
| Orbital Oedema |
2.4% |
| Osteonecrosis Of Jaw |
2.4% |
|
